drugset / Trial / NCT02447458
MLN3126 Single Rising Dose Study
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of MLN3126 when administered as a single dose of tablets at escalating dose levels in healthy participants.
Timeline
- Start
- 2013-09
- Primary completion
- 2014-01
- Completion
- 2014-02
Outcome
Outcome not reported
Stopped: “Site non-compliance to GCP (No safety concerns. See detailed description)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MLN3126 | Unknown | 300 mg | Oral |
| Subject | MLN3126 | Unknown | 600 mg | Oral |
| Subject | MLN3126 | Unknown | 1000 mg | Oral |
| Subject | MLN3126 | Unknown | 1500 mg | Oral |
| Subject | MLN3126 | Unknown | 2000 mg | Oral |
Indications
No indication recorded.